Roche
NEWS
It was a busy week for clinical trial updates. Here’s a look.
Roche is closing out its fourth-quarter with some house cleaning. The Swiss pharma giant announced in its earnings report that it was terminating studies of several mid- and late-stage assets, including two late-stage breast cancer programs.
It was a busy week for clinical trial news. Read on for more information.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
Roche announced topline data from two identical Phase III trials, TENAYA and LUCERNE, of faricimab in neovascular or “wet” age-related macular degeneration (nAMD).
With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.
The jury is still out on whether Roche’s arthritis drug, Actemra/RoActemra (tocilizumab), is helpful for the most severe cases of COVID-19.
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 8, 2020.
JOBS
IN THE PRESS